Narrow-band ultraviolet B treatment for diphenylcyclopropenone-induced vitiliginous lesions.

Topical immunotherapy, defined as the induction and periodic elicitation of an allergic contact dermatitis by topical application of potent contact allergens, has been used to treat conditions such as alopecia areata (AA) and recalcitrant warts since the 1970s (1). Topical immunotherapy with diphenylcyclopropenone (DPCP) is a safe and sometimes effective treatment for chronic extensive AA and viral warts (2). Pan et al. (3) have reported four patients with AA who developed vitiligo as a side-effect of DPCP immunotherapy. Pires et al. (1) also reported a case of vitiligo following DPCP therapy. We report here two cases, one patient with viral warts and one with AA, who developed vitiliginous lesions secondary to topical therapy with DPCP. The vitiliginous lesions were subsequently treated with narrow-band ultraviolet B (NB-UVB), and both patients showed excellent responses.